Welcome, Guest. Please login or register.
August 23, 2019, 03:46:57 pm

Login with username, password and session length

 

Members
Stats
  • Total Posts: 212
  • Total Topics: 101
  • Online Today: 14
  • Online Ever: 139
  • (October 31, 2018, 04:13:53 am)
Users Online
Users: 0
Guests: 7
Total: 7

Welcome!

Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Checkpoint Immunotherapies Show Promise for Liver Cancer  (Read 213 times)

Offline iana5252

  • Administrator
  • Newbie
  • *****
  • Posts: 5
    • View Profile
Checkpoint Immunotherapies Show Promise for Liver Cancer
« on: June 07, 2019, 09:34:54 am »
This news came out of ASCO, a big cancer doctor gathering in Chicago held in June every year. Here's some of Cancer Health's coverage of the news.

--------------------------------------------------

The PD-1 checkpoint inhibitor Keytruda (pembrolizumab) offered improved response rates for people with advanced liver cancer, although survival improvements did not meet statistical thresholds, according to research presented at the American Society of Clinical Oncology (ASCO) annual meeting this week in Chicago. Another study showed that pairing Opdivo (nivolumab) with a different type of immunotherapy improved outcomes considerably.

Hepatocellular carcinoma (HCC), the most common type of cancer that originates in the liver, is often detected late and is difficult to treat. Liver cancer generally does not respond well to traditional chemotherapy. Keytruda and Opdivo, as well as a handful of targeted therapies that interfere with cell growth and blood vessel development, have recently been approved to treat this cancer.

Keytruda and Opdivo are PD-1 checkpoint inhibitors that help the immune system fight cancer. PD-1, a checkpoint protein on T cells, helps regulate immune function. Some tumors can hijack PD-1 to turn off immune responses against them. Drugs that block the interaction between PD-1 and its binding partner, known as PD-L1, can release the brakes and restore T-cell activity. Yervoy is a different type of checkpoint inhibitor that blocks CTLA-4, which turns off immune responses by suppressing T-cell replication.

Read more...
https://www.cancerhealth.com/article/checkpoint-immunotherapies-liver-cancer

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.